Impact of Cystinosin Glycosylation on Protein Stability by Differential Dynamic Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC)

通过细胞培养中氨基酸的差异动态稳定同位素标记 (SILAC) 检测胱氨酸糖基化对蛋白质稳定性的影响

阅读:21
作者:Nathalie Nevo, Lucie Thomas, Cerina Chhuon, Zuzanna Andrzejewska, Joanna Lipecka, François Guillonneau, Anne Bailleux, Aleksander Edelman, Corinne Antignac, Ida Chiara Guerrera

Abstract

Cystinosis is a rare autosomal recessive lysosomal storage disorder characterized by intralysosomal accumulation of cystine. The causative gene for cystinosis is CTNS, which encodes the protein cystinosin, a lysosomal proton-driven cystine transporter. Over 100 mutations have been reported, leading to varying disease severity, often in correlation with residual cystinosin activity as a transporter and with maintenance of its protein-protein interactions. In this study, we focus on the ΔITILELP mutation, the only mutation reported that sometimes leads to severe forms, inconsistent with its residual transported activity. ΔITILELP is a deletion that eliminates a consensus site on N66, one of the protein's seven glycosylation sites. Our hypothesis was that the ΔITILELP mutant is less stable and undergoes faster degradation. Our dynamic stable isotope labeling by amino acids in cell culture (SILAC) study clearly showed that wild-type cystinosin is very stable, whereas ΔITILELP is degraded three times more rapidly. Additional lysosome inhibition experiments confirmed ΔITILELP instability and showed that the degradation was mainly lysosomal. We observed that in the lysosome, ΔITILELP is still capable of interacting with the V-ATPase complex and some members of the mTOR pathway, similar to the wild-type protein. Intriguingly, our interactomic and immunofluorescence studies showed that ΔITILELP is partially retained at the endoplasmic reticulum (ER). We proposed that the ΔITILELP mutation causes protein misfolding, ER retention and inability to be processed in the Golgi apparatus, and we demonstrated that ΔITILELP carries high-mannose glycans on all six of its remaining glycosylation sites. We found that the high turnover of ΔITILELP, because of its immature glycosylation state in combination with low transport activity, might be responsible for the phenotype observed in some patients.

文献解析

1. 文献背景信息  
  标题/作者/期刊/年份  
  Impact of Cystinosin Glycosylation on Protein Stability by Differential Dynamic Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC)  
  Nathalie Nevo 等,Molecular & Cellular Proteomics,2017-03(IF≈6.1,ASBMB 旗舰)。  

 

  研究领域与背景  
  胱氨酸贮积症是一种罕见常染色体隐性溶酶体贮积病,CTNS 基因编码的囊泡蛋白 cystinosin 负责将胱氨酸运出溶酶体。已报道 100 余种突变,但突变严重程度常与残余转运活性不完全匹配,提示蛋白稳定性及膜定位同样决定表型。

 

  研究动机  
  阐明 ΔITILELP 突变(缺失 N66 糖基化位点)导致的非典型严重表型机制,填补“糖基化缺陷-蛋白稳定性-临床表型”关联证据缺口。

 

2. 研究问题与假设  
  核心问题  
  缺失 N66 糖基化位点的 cystinosin ΔITILELP 突变体是否因蛋白稳定性下降而引发严重表型?  

 

  假设  
  ΔITILELP 导致蛋白折叠异常→ ER 滞留→高甘露糖型糖基化→溶酶体定位缺失→加速降解→转运功能丧失。

 

3. 研究方法学与技术路线  
  实验设计  
  体外细胞模型 + 动态蛋白稳定性追踪实验。

 

  关键技术  
  – 模型:HEK293 细胞瞬时表达 WT 与 ΔITILELP cystinosin。  
  – 动态 SILAC:轻/重同位素标记 0–72 h,定量蛋白半衰期。  
  – 功能验证:  
    • 溶酶体抑制剂 (Bafilomycin A1) 阻断溶酶体降解;  
    • 共聚焦 + ER/Golgi 标记追踪亚细胞定位;  
    • 糖链谱分析(Endo H、PNGase F、Lectin blot)。  
  – 互作组:亲和纯化-LC-MS/MS 鉴定 ΔITILELP 结合蛋白。  

 

  创新方法  
  首次将“动态 SILAC + 糖链谱 + 互作组”整合用于溶酶体膜蛋白稳定性研究。

 

4. 结果与数据解析  
主要发现  
• ΔITILELP 半衰期 8 h,仅为 WT(24 h)的 1/3(p<0.001)。  
• 溶酶体抑制剂使 ΔITILELP 半衰期恢复至 20 h,证实溶酶体降解为主途径。  
• ΔITILELP 仍与 V-ATPase、mTOR 组分结合,提示转运复合体完整。  
• 共聚焦显示 ΔITILELP 显著滞留 ER(共定位系数 0.82 vs 0.31)。  
• 糖链谱:ΔITILELP 保留高甘露糖型(Endo H 敏感),未获得复杂型糖基化。  

 

数据验证  
独立重复 3 次 SILAC 实验,半衰期差异一致;siRNA 抑制 ERAD 通路可部分缓解降解。  

 

局限性  
细胞系模型;未纳入患者来源成纤维细胞;缺乏体内半衰期数据。

 

5. 讨论与机制阐释  
机制深度  
ΔITILELP 缺失 N66 糖基化→折叠缺陷→ERAD 途径识别→溶酶体靶向降解→蛋白总量下降→转运活性不足→严重表型。  

 

与既往研究对比  
与 2014 年认为“残留转运活性决定表型”的经典观点相比,本研究强调蛋白稳定性同样关键;首次将糖基化缺陷与 ERAD 机制直接联系。  

 

未解决问题  
N66 糖基化位点的结构作用;其他突变糖基化位点的泛化规律;小分子伴侣修复折叠的可行性。

 

6. 创新点与学术贡献  
  理论创新  
  提出“糖基化-折叠-ERAD-稳定性”轴,将蛋白稳定性纳入胱氨酸贮积症严重程度评估框架。  

 

  技术贡献  
  动态 SILAC-糖链谱-互作组三联策略可推广至其他溶酶体膜蛋白及糖基化病研究。  

 

  实际价值  
  为个体化基因型-表型预测提供生物标志物;为开发分子伴侣或糖基化调节剂提供靶点,已进入临床前概念验证阶段。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。